webex: https://uwhealth.webex.com/uwhealth/j.php?MTID=m3e0079841c164c924e50bf2b3a66aaaf
Objectives:
- Describe the pathophysiology, etiology, and current medications available for the treatment of lupus nephritis
- Discuss the mechanism of action, indications for use, monitoring, and adverse reactions associated with obinutuzumab
- Summarize the results of a recent randomized, double blind, placebo-controlled trial regarding the use of obinutuzumab for the treatment of class III or IV lupus nephritis
- Describe the mechanism of action of GLP-1 receptor agonists and effect on gastric emptying time
- Identify potential concerns for perioperative use and define current recommendations
- Discuss organ-specific considerations and future directions
- Identify the need for expanding the solid organ donor pool and how that can be achieved by including hepatitis B and C positive donors
- Describe the pharmacologic therapies currently utilized in solid organ transplantation from a hepatitis C positive donor
- Explain the considerations for using a hepatitis B positive donor in solid organ transplantation and possible pharmacologic interventions
Session date:
11/07/2023 - 1:00pm to 2:00pm CST
Location:
In-person and Virtually
Will be determined by room availability
600 Highland Ave
Madison, WI
53705
United States
See map: Google Maps
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 ACPE Contact Hours - Pharmacist Technician
- 1.00 University of Wisconsin–Madison Continuing Education Hours
Add to calendar:
Discloser List CME Internal Report
Presenter(s):
Amanda Egbert
Clara Nickel
Maria Golovkina